{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:30:59Z","timestamp":1792009859816,"version":"4.4.0"},"reference-count":75,"publisher":"American Association for Cancer Research (AACR)","issue":"24","funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K08-CA282987"],"award-info":[{"award-number":["K08-CA282987"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005155","name":"Azrieli Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005155","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","award":["1944\/22"],"award-info":[{"award-number":["1944\/22"]}],"id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","award":["607\/20"],"award-info":[{"award-number":["607\/20"]}],"id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020260","name":"Helen and Martin Kimmel Center for Molecular Design, Weizmann Institute of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020260","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016293","name":"Elsie and Marvin Dekelboum Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016293","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012273","name":"Lotte and John Hecht Memorial Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012273","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["101055341-TROJAN-Cell"],"award-info":[{"award-number":["101055341-TROJAN-Cell"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["259373024 \u2013"],"award-info":[{"award-number":["259373024 \u2013"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["TRR 167"],"award-info":[{"award-number":["TRR 167"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment landscape for relapsed\/refractory B-cell malignancies. Despite its success, approximately 60% of patients experience treatment failure, underscoring the need to better understand the determinants of response and resistance. We performed single-cell RNA sequencing of pretreatment peripheral blood samples and anti-CD19 CAR T-cell products from 57 diffuse large B-cell lymphomas (DLBCL), correlating molecular and cellular features with clinical outcomes. At the time of leukapheresis, responders presented elevated levels of CD16+ monocytes and CD4+ effector memory T cells. In contrast, nonresponders showed an inflammation-driven gene expression signature across T-cell and myeloid compartments, marked by upregulation of TNF\u03b1 response signaling pathways. Notably, the presence of malignant or healthy B cells (13 of 57 patients) was strongly associated with a favorable response. These findings shed light on the immune landscape conducive to successful CAR T-cell therapy and offer a molecular framework for developing personalized tools to improve patient selection, stratification, and the design of next-generation CAR T-cell treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Single-cell analysis of pretreatment peripheral blood from diffuse large B-cell lymphoma identified immune cell populations and genetic signatures correlated with CAR T-cell outcomes, informing patient selection, treatment strategies, and next-generation CAR T development.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/0008-5472.can-25-3596","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:43:38Z","timestamp":1760114618000},"page":"5066-5083","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Distinct Cellular and Molecular Patterns in Pretreatment Peripheral Blood Are Associated with CAR T-cell Outcomes in Diffuse Large B-cell Lymphoma"],"prefix":"10.1158","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9698-1306","authenticated-orcid":false,"given":"Anna","family":"Gurevich-Shapiro","sequence":"first","affiliation":[{"name":"1Systems Immunology Department, Weizmann Institute of Science, Rehovot, Israel."},{"name":"2Division of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel."},{"name":"3Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0419-2153","authenticated-orcid":false,"given":"Pascale","family":"Zwicky","sequence":"additional","affiliation":[{"name":"1Systems Immunology Department, Weizmann Institute of Science, Rehovot, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4936-6023","authenticated-orcid":false,"given":"Eitan","family":"Winter","sequence":"additional","affiliation":[{"name":"1Systems Immunology Department, Weizmann Institute of Science, Rehovot, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9204-8460","authenticated-orcid":false,"given":"Mor","family":"Zada","sequence":"additional","affiliation":[{"name":"1Systems Immunology Department, Weizmann Institute of Science, Rehovot, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4676-0618","authenticated-orcid":false,"given":"Noam","family":"Shapira","sequence":"additional","affiliation":[{"name":"1Systems Immunology Department, Weizmann Institute of Science, Rehovot, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5995-9230","authenticated-orcid":false,"given":"Oren","family":"Barboy","sequence":"additional","affiliation":[{"name":"1Systems Immunology Department, Weizmann Institute of Science, Rehovot, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0968-9954","authenticated-orcid":false,"given":"Paulina","family":"Chalan","sequence":"additional","affiliation":[{"name":"1Systems Immunology Department, Weizmann Institute of Science, Rehovot, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5857-3383","authenticated-orcid":false,"given":"Reut","family":"Sharet-Eshed","sequence":"additional","affiliation":[{"name":"1Systems Immunology Department, Weizmann Institute of Science, Rehovot, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3289-8818","authenticated-orcid":false,"given":"Merav","family":"Kedmi","sequence":"additional","affiliation":[{"name":"4Department of Life Sciences Core Facilities, Weizmann Institute of Science, Rehovot, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6890-9753","authenticated-orcid":false,"given":"Florian","family":"Ingelfinger","sequence":"additional","affiliation":[{"name":"1Systems Immunology Department, Weizmann Institute of Science, Rehovot, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8837-5119","authenticated-orcid":false,"given":"Truong San","family":"Phan","sequence":"additional","affiliation":[{"name":"1Systems Immunology Department, Weizmann Institute of Science, Rehovot, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9020-2364","authenticated-orcid":false,"given":"Eyal","family":"David","sequence":"additional","affiliation":[{"name":"1Systems Immunology Department, Weizmann Institute of Science, Rehovot, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9827-8032","authenticated-orcid":false,"given":"Roni","family":"Shouval","sequence":"additional","affiliation":[{"name":"5Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."},{"name":"6Department of Medicine, Weill Cornell Medicine, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1167-1307","authenticated-orcid":false,"given":"Danny","family":"Luan","sequence":"additional","affiliation":[{"name":"5Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."},{"name":"6Department of Medicine, Weill Cornell Medicine, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4629-0528","authenticated-orcid":false,"given":"Sandeep S.","family":"Raj","sequence":"additional","affiliation":[{"name":"5Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5943-6974","authenticated-orcid":false,"given":"Michael","family":"Shapiro","sequence":"additional","affiliation":[{"name":"3Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6882-9603","authenticated-orcid":false,"given":"Orit","family":"Itzhaki","sequence":"additional","affiliation":[{"name":"3Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel."},{"name":"7Division of Hematology, Sheba Medical Center, Ramat Gan and Tel Aviv University, Tel Aviv, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3674-7842","authenticated-orcid":false,"given":"Noa","family":"Golan-Accav","sequence":"additional","affiliation":[{"name":"3Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel."},{"name":"7Division of Hematology, Sheba Medical Center, Ramat Gan and Tel Aviv University, Tel Aviv, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7448-869X","authenticated-orcid":false,"given":"Abraham","family":"Avigdor","sequence":"additional","affiliation":[{"name":"3Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel."},{"name":"7Division of Hematology, Sheba Medical Center, Ramat Gan and Tel Aviv University, Tel Aviv, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8663-444X","authenticated-orcid":false,"given":"Irit","family":"Avivi","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel."},{"name":"3Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5389-9668","authenticated-orcid":false,"given":"Assaf","family":"Weiner","sequence":"additional","affiliation":[{"name":"1Systems Immunology Department, Weizmann Institute of Science, Rehovot, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8683-6930","authenticated-orcid":false,"given":"Ron","family":"Ram","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel."},{"name":"3Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2968-877X","authenticated-orcid":false,"given":"Ido","family":"Amit","sequence":"additional","affiliation":[{"name":"1Systems Immunology Department, Weizmann Institute of Science, Rehovot, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"2025121503111117800_bib1","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"key":"2025121503111117800_bib2","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1158\/2159-8290.CD-18-1314","article-title":"Na\u00efve T-cell deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers","volume":"9","author":"Das","year":"2019","journal-title":"Cancer Discov"},{"key":"2025121503111117800_bib3","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat Med"},{"key":"2025121503111117800_bib4","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI125423","article-title":"CD19 CAR T cell product and disease attributes predict leukemia remission durability","volume":"129","author":"Finney","year":"2019","journal-title":"J Clin Invest"},{"key":"2025121503111117800_bib5","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"key":"2025121503111117800_bib6","first-page":"578","article-title":"Long-term Follow-up ZUMA-1: a pivotal trial of axicabtagene ciloleucel (Axi-Cel; KTE-C19) in patients with refractory aggressive non-hodgkin lymphoma (NHL)","volume":"130","author":"Neelapu","year":"2017","journal-title":"Blood"},{"key":"2025121503111117800_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-13880-1","article-title":"Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy","volume":"11","author":"Sheih","year":"2020","journal-title":"Nat Commun"},{"key":"2025121503111117800_bib8","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1182\/blood.2024024381","article-title":"Baseline immune state and T-cell clonal kinetics are associated with durable response to CAR-T therapy in large B-cell lymphoma","volume":"144","author":"Maurer","year":"2024","journal-title":"Blood"},{"key":"2025121503111117800_bib9","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1038\/s41591-022-01959-0","article-title":"Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma","volume":"28","author":"Haradhvala","year":"2022","journal-title":"Nat Med"},{"key":"2025121503111117800_bib10","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/blood.2022015601","article-title":"Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma","volume":"140","author":"Cherng","year":"2022","journal-title":"Blood"},{"key":"2025121503111117800_bib11","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.21.02143","article-title":"Impact of TP53 genomic alterations in large B-cell lymphoma treated with CD19-chimeric antigen receptor T-cell therapy","volume":"40","author":"Shouval","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025121503111117800_bib12","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/bloodadvances.2021006845","article-title":"Genetic landscapes and curative effect of CAR T-cell immunotherapy in patients with relapsed or refractory DLBCL","volume":"7","author":"Shi","year":"2023","journal-title":"Blood Adv"},{"key":"2025121503111117800_bib13","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1182\/hematology.2023000472","article-title":"Recognizing, defining, and managing CAR-T hematologic toxicities","volume":"2023","author":"Rejeski","year":"2023","journal-title":"Hematology"},{"key":"2025121503111117800_bib14","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1182\/hematology.2023000436","article-title":"CAR T-cell therapy in aggressive lymphomas-identifying prognostic and predictive markers","volume":"2023","author":"Mussetti","year":"2023","journal-title":"Hematol Am Soc Hematol Educ Progr"},{"key":"2025121503111117800_bib15","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1158\/2159-8290.CD-23-0010","article-title":"In synergy: optimizing CAR T development and personalizing patient care using single-cell technologies","volume":"13","author":"Barboy","year":"2023","journal-title":"Cancer Discov"},{"key":"2025121503111117800_bib16","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","article-title":"Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion","volume":"19","author":"Amini","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"2025121503111117800_bib17","first-page":"251","article-title":"Point-of-care anti-CD19 CAR T-cells for treatment of relapsed and refractory aggressive B-cell lymphoma","volume":"28","author":"Kedmi","year":"2022","journal-title":"Transpl Cell Ther"},{"key":"2025121503111117800_bib18","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1126\/science.1247651","article-title":"Massively parallel single-cell RNA-seq for marker-free decomposition of tissues into cell types","volume":"343","author":"Jaitin","year":"2014","journal-title":"Science"},{"key":"2025121503111117800_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/gigascience\/giaa151","article-title":"SoupX removes ambient RNA contamination from droplet-based single-cell RNA sequencing data","volume":"9","author":"Young","year":"2020","journal-title":"Gigascience"},{"key":"2025121503111117800_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13059-019-1812-2","article-title":"MetaCell: analysis of single-cell RNA-seq data using K-nn graph partitions","volume":"20","author":"Baran","year":"2019","journal-title":"Genome Biol"},{"key":"2025121503111117800_bib21","article-title":"Browse human gene sets","author":"GSEA | MSigDB"},{"key":"2025121503111117800_bib22","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1126\/science.aad0501","article-title":"Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq","volume":"352","author":"Tirosh","year":"2016","journal-title":"Science"},{"key":"2025121503111117800_bib23","article-title":"Inferring CNV from single-cell RNA-Seq","author":"GitHub - Broadinstitute\/Infercnv"},{"key":"2025121503111117800_bib24","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","article-title":"Fast, sensitive and accurate integration of single-cell data with harmony","volume":"16","author":"Korsunsky","year":"2019","journal-title":"Nat Methods"},{"key":"2025121503111117800_bib25","doi-asserted-by":"crossref","first-page":"e2203828120","DOI":"10.1073\/pnas.2203828120","article-title":"Sccomp: robust differential composition and variability analysis for single-cell data","volume":"120","author":"Mangiola","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025121503111117800_bib26","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1158\/2643-3230.BCD-24-0163","article-title":"Dynamics of immune reconstitution and impact on outcomes across CAR-T cell products in large B-cell lymphoma","volume":"6","author":"Luan","year":"2025","journal-title":"Blood Cancer Discov"},{"key":"2025121503111117800_bib27","first-page":"2825","article-title":"Scikit-learn: machine learning in python","volume":"12","author":"Pedregosa","year":"2011","journal-title":"J Mach Learn Res"},{"key":"2025121503111117800_bib28","first-page":"785","article-title":"XGBoost: a scalable tree boosting system","author":"Chen","year":"2016","journal-title":"Proc ACM SIGKDD Int Conf Knowl Discov Data Min"},{"key":"2025121503111117800_bib29","first-page":"2623","article-title":"Optuna: a next-generation hyperparameter optimization framework","author":"Akiba","year":"2019","journal-title":"Proc ACM SIGKDD Int Conf Knowl Discov Data Min"},{"key":"2025121503111117800_bib30","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-Cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"2025121503111117800_bib31","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"2025121503111117800_bib32","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-Hodgkin lymphoma: the lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"2025121503111117800_bib33","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"2025121503111117800_bib34","doi-asserted-by":"crossref","first-page":"718","DOI":"10.3324\/haematol.2019.243626","article-title":"Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma","volume":"106","author":"Autio","year":"2021","journal-title":"Haematologica"},{"key":"2025121503111117800_bib35","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1182\/blood.2024027877","article-title":"Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment","volume":"146","author":"Pelzl","year":"2025","journal-title":"Blood"},{"key":"2025121503111117800_bib36","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1038\/leu.2017.41","article-title":"Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL","volume":"31","author":"Duell","year":"2017","journal-title":"Leukemia"},{"key":"2025121503111117800_bib37","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/s41591-022-01960-7","article-title":"Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy","volume":"28","author":"Good","year":"2022","journal-title":"Nat Med"},{"key":"2025121503111117800_bib38","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1600-065X.2012.01150.x","article-title":"Metabolic switching and fuel choice during T-cell differentiation and memory development","volume":"249","author":"van der Windt","year":"2012","journal-title":"Immunol Rev"},{"key":"2025121503111117800_bib39","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41590-021-01078-x","article-title":"Surface phenotypes of naive and memory B cells in mouse and human tissues","volume":"23","author":"Weisel","year":"2022","journal-title":"Nat Immunol"},{"key":"2025121503111117800_bib40","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1038\/s41591-018-0269-2","article-title":"Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma","volume":"24","author":"Ledergor","year":"2018","journal-title":"Nat Med"},{"key":"2025121503111117800_bib41","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/ejh.12427","article-title":"B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells","volume":"94","author":"Seda","year":"2015","journal-title":"Eur J Haematol"},{"key":"2025121503111117800_bib42","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1038\/s41375-019-0508-7","article-title":"Next-generation sequencing of immunoglobulin gene rearrangements for clonality assessment: a technical feasibility study by EuroClonality-NGS","volume":"33","author":"Scheijen","year":"2019","journal-title":"Leukemia"},{"key":"2025121503111117800_bib43","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMra2102568","article-title":"Marginal-zone lymphomas","volume":"386","author":"Rossi","year":"2022","journal-title":"N Engl J Med"},{"key":"2025121503111117800_bib44","first-page":"103425","article-title":"Cytogenetics in the management of mature B-cell non-Hodgkin lymphomas: guidelines from the Groupe Francophone de Cytog\u00e9n\u00e9tique Hematologique (GFCH)","volume":"71","author":"Lefebvre","year":"2023","journal-title":"Curr Res Transl Med"},{"key":"2025121503111117800_bib45","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nri2217","article-title":"Germinal centres: role in B-cell physiology and malignancy","volume":"8","author":"Klein","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"2025121503111117800_bib46","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"2025121503111117800_bib47","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41591-023-02754-1","article-title":"Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma","volume":"30","author":"Locke","year":"2024","journal-title":"Nat Med"},{"key":"2025121503111117800_bib48","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.ccell.2025.06.002","article-title":"Large B cell lymphoma microenvironment archetype profiles","volume":"43","author":"Li","year":"2025","journal-title":"Cancer Cell"},{"key":"2025121503111117800_bib49","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4+ CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"2025121503111117800_bib50","doi-asserted-by":"crossref","first-page":"e007803","DOI":"10.1136\/jitc-2023-007803","article-title":"CD8+ chimeric antigen receptor T cells manufactured in absence of CD4+ cells exhibit hypofunctional phenotype","volume":"11","author":"Lee","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2025121503111117800_bib51","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1158\/1078-0432.CCR-23-0178","article-title":"Single-cell RNA analysis reveals cell-intrinsic functions of CAR T cells correlating with response in a phase II study of lymphoma patients","volume":"29","author":"Sar\u00e9n","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2025121503111117800_bib52","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.ccell.2023.08.015","article-title":"A single-cell atlas of CD19 chimeric antigen receptor T cells","volume":"41","author":"Li","year":"2023","journal-title":"Cancer Cell"},{"key":"2025121503111117800_bib53","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41571-023-00729-2","article-title":"Advancing CAR T cell therapy through the use of multidimensional omics data","volume":"204","author":"Yang","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"2025121503111117800_bib54","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1158\/1078-0432.CCR-22-0164","article-title":"Phenotypic composition of commercial anti-CD19 CAR T cells affects in vivo expansion and disease response in patients with large B-cell lymphoma","volume":"28","author":"Monfrini","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025121503111117800_bib55","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1038\/s41591-022-01916-x","article-title":"Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma","volume":"28","author":"Scholler","year":"2022","journal-title":"Nat Med"},{"key":"2025121503111117800_bib56","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1158\/2159-8290.CD-22-1276","article-title":"A novel autologous CAR-T therapy, YTB323, with preserved T-cell stemness shows enhanced CAR T-cell efficacy in preclinical and early clinical development","volume":"13","author":"Dickinson","year":"2023","journal-title":"Cancer Discov"},{"key":"2025121503111117800_bib57","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1158\/2159-8290.CD-20-1677","article-title":"Integrative bulk and single-cell profiling of premanufacture t-cell populations reveals factors mediating long-term persistence of car t-cell therapy","volume":"11","author":"Chen","year":"2021","journal-title":"Cancer Discov"},{"key":"2025121503111117800_bib58","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/nm.4505","article-title":"Single-cell developmental classification of B cell precursor acute lymphoblastic leukemia at diagnosis reveals predictors of relapse","volume":"244","author":"Good","year":"2018","journal-title":"Nat Med"},{"key":"2025121503111117800_bib59","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/s41375-023-02129-y","article-title":"Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed\/refractory myeloma","volume":"38","author":"Fischer","year":"2024","journal-title":"Leukemia"},{"key":"2025121503111117800_bib60","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2020-137650","article-title":"Cite-seq profiling of T cells in multiple myeloma patients undergoing BCMA targeting CAR-T or bites immunotherapy","volume":"136","author":"Leblay","year":"2020","journal-title":"Blood"},{"key":"2025121503111117800_bib61","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1182\/bloodadvances.2021006563","article-title":"HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma","volume":"7","author":"Bourbon","year":"2023","journal-title":"Blood Adv"},{"key":"2025121503111117800_bib62","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jcyt.2016.04.003","article-title":"Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells","volume":"18","author":"Stroncek","year":"2016","journal-title":"Cytotherapy"},{"key":"2025121503111117800_bib63","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.omtm.2021.02.002","article-title":"Enriching leukapheresis improves T cell activation and transduction efficiency during CAR T processing","volume":"20","author":"Noaks","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2025121503111117800_bib64","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/bloodadvances.2024012563","article-title":"Monocytes in leukapheresis products affect the outcome of CD19\u2013targeted CAR T-cell therapy in patients with lymphoma","volume":"8","author":"Carniti","year":"2024","journal-title":"Blood Adv"},{"key":"2025121503111117800_bib65","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.stem.2014.01.007","article-title":"Conversion of danger signals into cytokine signals by hematopoietic stem and progenitor cells for regulation of stress-induced hematopoiesis","volume":"14","author":"Zhao","year":"2014","journal-title":"Cell Stem Cell"},{"key":"2025121503111117800_bib66","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/s41591-025-03532-x","article-title":"An inflammatory biomarker signature of response to CAR-T cell therapy in Non-Hodgkin lymphoma","volume":"31","author":"Raj","year":"2025","journal-title":"Nat Med"},{"key":"2025121503111117800_bib67","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1182\/blood.2020007445","article-title":"Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma","volume":"137","author":"Jain","year":"2021","journal-title":"Blood"},{"key":"2025121503111117800_bib68","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1\/2 trial","volume":"303","author":"Marin","year":"2024","journal-title":"Nat Med"},{"key":"2025121503111117800_bib69","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood.2024026564","article-title":"High-dimensional data bridges for CARs","volume":"144","author":"Fiorenza","year":"2024","journal-title":"Blood"},{"key":"2025121503111117800_bib70","doi-asserted-by":"crossref","first-page":"7457","DOI":"10.1182\/blood-2022-170629","article-title":"Circulating tumor DNA correlation with lymphoma response and survival outcomes at multiple time points of anti - CD19 CAR T cell therapy","volume":"140","author":"Caimi","year":"2022","journal-title":"Blood"},{"key":"2025121503111117800_bib71","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1007\/s00259-023-06554-0","article-title":"Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy","volume":"51","author":"Voltin","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2025121503111117800_bib72","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12185-016-2039-6","article-title":"Biology and clinical application of CAR T cells for B cell malignancies","volume":"104","author":"Davila","year":"2016","journal-title":"Int J Hematol"},{"key":"2025121503111117800_bib73","doi-asserted-by":"crossref","first-page":"e134612","DOI":"10.1172\/jci.insight.134612","article-title":"Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy","volume":"5","author":"Chen","year":"2020","journal-title":"JCI Insight"},{"key":"2025121503111117800_bib74","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/ajh.27349","article-title":"Dendritic cell vaccines extend CAR T-cell persistence and improve the efficacy of CD19 CAR T-cell therapy in refractory or relapsed adult B-ALL patients","volume":"99","author":"Tu","year":"2024","journal-title":"Am J Hematol"},{"key":"2025121503111117800_bib75","doi-asserted-by":"crossref","first-page":"eabd4344","DOI":"10.1126\/sciimmunol.abd4344","article-title":"A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity","volume":"6","author":"Boulch","year":"2021","journal-title":"Sci Immunol"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/doi\/10.1158\/0008-5472.CAN-25-3596\/3659252\/can-25-3596.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/85\/24\/5066\/3711645\/can-25-3596.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/85\/24\/5066\/3711645\/can-25-3596.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T08:11:28Z","timestamp":1765786288000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/85\/24\/5066\/770543\/Distinct-Cellular-and-Molecular-Patterns-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":75,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2025,10,10]]},"published-print":{"date-parts":[[2025,12,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-25-3596","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]}}}